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Order Set Details
Clinical Overview Synopses
 ClinicalKey Clinical Overviews provide additional specific guidance for:
 Coronavirus: novel coronavirus (COVID-19) infection 
Guidance
Coronavirus (COVID-19), Clinical Overview Synopsis ~
KEY POINTS
COVID-19 (coronavirus disease 2019) is respiratory tract infection due to a novel coronavirus, SARS-
CoV-2 (initially called 2019-nCoV); as of March 11, 2020, extent of infection was declared pandemic by
the WHO
Virus is thought to be zoonotic in origin, but the animal reservoir is not yet known, and human-to-human
transmission is widespread
Infection ranges from asymptomatic to severe; symptoms include fever, cough, and (in moderate to
severe cases) dyspnea; disease may evolve over the course of a week or more from mild to severe.
Upper respiratory tract symptoms (eg, rhinorrhea, sore throat) are uncommon
A significant proportion of clinically evident cases are severe; the mortality rate among diagnosed cases is
generally about 2% to 3% but varies by country
Infection should be suspected based on presentation with a clinically compatible history and known or
likely exposure (eg, residence in or travel to an affected area within the past 14 days, exposure to a
known or suspected case, exposure to a health care setting in which patients with severe respiratory tract
infections are managed)
Chest imaging in symptomatic patients almost always shows abnormal findings, usually including bilateral
infiltrates; laboratory findings are variable but typically include lymphopenia and elevated lactate
dehydrogenase and transaminase levels
Diagnosis is confirmed by detection of viral RNA on polymerase chain reaction test of upper or lower
respiratory tract specimens or serum specimens
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There is no specific antiviral therapy, although compassionate use and trial protocols for several agents
are underway; treatment is largely supportive, consisting of supplemental oxygen and conservative fluid
administration
Most common complications are acute respiratory distress syndrome and septic shock; myocardial, renal,
and multiorgan failure have been reported
There is no vaccine available to prevent this infection; infection control measures are the mainstay of
prevention (ie, hand and cough hygiene; physical distancing; standard, contact, and airborne precautions
in health care)
URGENT ACTION
Triage screening is recommended at registration for medical care to identify patients with symptoms and
exposure history that suggest the possibility of COVID-19, and to promptly institute isolation measures
Patients with respiratory distress require prompt administration of supplemental oxygen; patients with
respiratory failure require intubation
Patients in shock require urgent fluid resuscitation and administration of empiric antimicrobial therapy to
cover possible bacterial pathogens and/or influenza
PITFALLS
It is probable that persons with prodromal or asymptomatic infection may spread infection, making
effective prevention more challenging; regardless, physical distancing is vital to slowing transmission
enough to avoid overwhelming health systems
Knowledge of this disease is incomplete and evolving; moreover, coronaviruses are known to mutate and
recombine often, presenting an ongoing challenge to our understanding and to clinical management
 




Discontinuation of Isolation, COVID-19 ~
CDC offers several strategies depending on whether the patient was symptomatic at any time or was
asymptomatic throughout. These apply to patients who were cared for in hospital or at home. Note that if patients
are discharged from hospital before they meet these criteria, appropriate precautions must be maintained in the
setting to which they are discharged (eg, other healthcare facility or home) 
In symptomatic patients, precautions should be maintained until the following conditions are met:
Symptom-based
Subjective and objective evidence of improvement in respiratory symptoms and absence of fever
without use of antipyretic medication for 72 hours, and
At least 10 days since onset of symptoms
Test-based
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Subjective and objective evidence of clinical improvement, including absence of fever without use
of antipyretic medication, and
Demonstration of negative results of molecular assays for SARS-CoV-2 RNA on 2 consecutive
respiratory specimens obtained at least 24 hours apart (a single specimen suffices for each test)
In asymptomatic patients precautions should be maintained until the following conditions are met:
Time-based
At least 10 days since first positive COVID-19 molecular test result was obtained
Test-based
Demonstration of negative results of molecular assays for SARS-CoV-2 RNA on 2 consecutive
respiratory specimens obtained at least 24 hours apart (a single specimen suffices for each test)
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
Published By: Elsevier
 Discharge to Home
 Discharge to Long Term Acute Care
 Discharge to Rehab
 Discharge to Skilled facility
Vital Signs and Monitors
 Monitoring
 Temperature 2 times a day 
Guidance
At Home Monitoring, COVID-19 ~
Patients who do not require admission should self-monitor temperature and symptoms, and they should return
for reevaluation if symptoms worsen; deterioration may occur a week or more into the course of illness
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
Published By: Elsevier
Activity
 Up ad lib
 Ambulate with assistance
 Bed rest
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General Care
 Patient Education 
Guidance
At Home Monitoring, COVID-19 ~
Patients who do not require admission should self-monitor temperature and symptoms, and they should return for
reevaluation if symptoms worsen; deterioration may occur a week or more into the course of illness
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
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Patients Managed at Home, COVID-19 ~
Patient is encouraged to stay at home except to seek medical care, to self-isolate to a single area of the house
(preferably with a separate bathroom), to practice good hand and cough hygiene, and to wear a cloth face cover
during any contact with household members
Patients should be advised that if a need for medical care develops, they should call their health care
provider in advance so that proper isolation measures can be undertaken promptly on their arrival at the
health care setting
Household members/caregivers should:
Ideally, wear face mask, gown, and gloves when caring for patient, and remove and discard all when
leaving the room (do not reuse); however, if some of these supplies are absent, wear cloth face cover and
scrupulously wash hands and laundry
Dispose of disposable items in a container lined with a trash bag that can be removed and tied off
or sealed before disposal in household trash
Wash hands for at least 20 seconds after all contact; an alcohol-based hand sanitizer is acceptable if soap
and water are not available
Not share personal items such as towels, dishes, or utensils before proper cleaning
Wash laundry and high-touch surfaces frequently
Wear disposable gloves to handle dirty laundry and use highest possible temperatures for washing
and drying, based on washing instructions on the items
Clean surfaces with diluted bleach solution or an EPA-approved disinfectant
Restrict contact to minimum number of caregivers and, in particular, ensure that persons with underlying
medical conditions are not exposed to the patient
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
Published By: Elsevier
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 Patient education: Infection Education
 Patient education: Monitoring body temperature ; At least once a day
 Patient education: Tobacco/Second-Hand Smoke Counseling  
Guidance
Tobacco Cessation Interventions
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians:
Ask all adults about tobacco use
Advise them to stop using tobacco
Provide behavioral interventions and U.S. Food and Drug Administration (FDA)–approved
pharmacotherapy for cessation to adults who use tobacco
In addition, the USPSTF recommends that clinicians:
Ask all pregnant women about tobacco use
Advise them to stop using tobacco
Provide behavioral interventions for cessation to pregnant women who use tobacco
The USPSTF concludes that the current evidence is insufficient to assess the balance of
benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women.
Also, the USPSTF concludes that the current evidence is insufficient to recommend electronic nicotine
delivery systems (ENDS) for tobacco cessation in adults, including pregnant women. The USPSTF
recommends that clinicians direct patients who smoke tobacco to other cessation interventions with
established effectiveness and safety.
 
Siu AL; U.S. Preventive Services Task Force. . Behavioral and Pharmacotherapy Interventions for Tobacco
Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force
Recommendation Statement. Ann Intern Med. 2015;163(8), 622-634. Source
Published By: Elsevier
Quality Measure
NQF 1651; NQF 1654; NQF 1656. Inpatient tobacco cessation bundle, includes discharge
NQF 1651; NQF 1654; and NQF 1656 are bundled, inpatient quality measures from the Joint Commission
related to tobacco use screening and treatment, and referral to treatment at discharge.
 
1.)  NQF 1651. TOB-1: Tobacco Use Screening. 
Hospitalized patients aged >18 years, who are screened during the hospital stay for tobacco use
(cigarettes, smokeless tobacco, pipe and cigars) within the past 30 days. This measure is intended to
be used as part of a set of linked measures addressing Tobacco Use. Source
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 2.)  NQF 1654. TOB-2: Tobacco Use Treatment Provided or Offered and the subset measure TOB-2a
Tobacco Use Treatment. 
The measure is reported as an overall rate, which includes all hospitalized patients aged >18 years, to
whom tobacco use treatment was provided during the hospital stay, or offered and refused; and a
second rate, a subset of the first, which includes only those patients who received tobacco use
treatment during the hospital stay. These measures are intended to be used as part of a set of
measures addressing Tobacco Use. 
TOB-2: The number of patients who received or refused practical counseling to quit AND received or
refused FDA-approved cessation medications.
TOB-2a: The number of patients who received practical counseling to quit AND received FDA-
approved cessation medications. Source
 
3.)  NQF1656. TOB-3: Tobacco Use Treatment Provided or Offered at Discharge and the subset
measure
TOB-3a: Tobacco Use Treatment at Discharge. The measure is reported as an overall rate which
includes all hospitalized patients aged >18 years, to whom tobacco use treatment was provided, or
offered and refused, at the time of hospital discharge; and a second rate, a subset of the first, which
includes only those patients who received tobacco use treatment at discharge. Treatment at discharge
includes a referral to outpatient counseling and a prescription for one of the FDA-approved tobacco
cessation medications. These measures are intended to be used as part of a set of linked measures
addressing Tobacco Use. 
TOB-3: The number of patients who received or refused evidence-based outpatient counseling AND
received or refused a prescription for FDA-approved cessation medication at discharge.
TOB-3a: The number of patients who were referred to evidence-based outpatient counseling AND
received a prescription for FDA-approved cessation medication at discharge. Source
 
Steward: Joint Commission. National Quality Strategy Priorities: Health and Well-Being.
Care Setting: Hospital/Acute Care Facility.






 Document influenza and pneumococcal immunization status 
Quality Measure
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NQF 1659. Influenza Immunization, Inpatient, 6 Months and Older, discharge
Inpatients aged >6 months, discharged during October, November, December, January, February or March,
who are screened for influenza vaccine status and vaccinated prior to discharge, if indicated. 
 
Steward: Centers for Medicare & Medicaid Services.
Use in Federal Program: Hospital Inpatient Quality Reporting. 
Care Setting: Hospital/Acute Care Facility . 
National Quality Forum-endorsed measure. Source
Published By: Elsevier
 Document acceptance or rejection of alcohol/substance abuse discharge treatment  
Guidance
Alcohol and Substance Abuse Screening
The U. S. Preventive Services Task Force (USPSTF) recommends that clinicians screen adults aged 18 years
or older for alcohol misuse and provide persons engaged in risky or hazardous drinking with brief behavioral
counseling interventions to reduce alcohol misuse. (Recommendation: Grade B)
 
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of
screening adolescents, adults, and pregnant women for illicit drug use. (Recommendation: Grade I)
 
For alcohol use, briefly screen patients with the four-question CAGE questionnaire, which has been shown to
be effective in identifying problem alcohol use
Two or more affirmative answers to the CAGE questions below (with modifications for drug
use) indicate a high probability of dependence:
1. Have you ever felt that you should Cut down on your drinking (or drug use)?
2. Have people Annoyed you by criticizing your drinking (or drug use)?
3. Have you ever felt bad or Guilty about your drinking (or drug use)?
4. Have you ever had a drink (used drugs) first thing in the morning to steady your nerves or to get
rid of a hangover (Eye-opener)?
Click for CAGE Questions for Alcohol Use
Click for AUDIT-C for Alcohol Use
 
US Preventive Services Task Force. (2013). Published Recommendations for Primary Care Practice. Alcohol
Misuse: Screening and Behavioral Counseling Interventions in Primary Care. Source
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 Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies.
Clin Invest Med. 2007;30(1), 33-41. Source
Published By: Elsevier
Quality Measure
NQF 1664. SUB-3: Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge;
SUB-3a: Alcohol & Other Drug Use Disorder Treatment at Discharge
1. The measure is reported as:
An overall rate, which includes all hospitalized patients aged >18 years, to whom alcohol or drug use
disorder treatment was provided, or offered and refused, at the time of hospital discharge; and
A second rate, a subset of the first, which includes only those patients who received alcohol or drug
use disorder treatment at discharge
2. The Provided or Offered rate (SUB-3) describes patients who:
Are identified with alcohol or drug use disorder
Receive or refuse at discharge a prescription for FDA-approved medications for alcohol or drug use
disorder
Receive or refuse a referral for addictions treatment
3. The Alcohol and Other Drug Disorder Treatment at Discharge (SUB-3a) rate describes only those who
receive:
A prescription for FDA-approved medications for alcohol or drug use disorder
Referral for addictions treatment
Those who refused are not included.
4. These measures are intended to be used as part of a set of 4 linked measures addressing Substance Use
(SUB-1 Alcohol Use Screening; SUB-2 Alcohol Use Brief Intervention Provided or Offered; SUB-3 Alcohol and
Other Drug Use Disorder Treatment Provided or Offered at Discharge; SUB-4 Alcohol and Drug Use:
Assessing Status after Discharge)
SUB-3: The number of patients who received or refused at discharge a prescription for medication for
treatment of alcohol or drug use disorder, OR received or refused a referral for addictions treatment.
SUB-3a: The number of patients who received a prescription at discharge for medication for treatment of
alcohol or drug use disorder, OR a referral for addictions treatment.
Steward: The Joint Commission.
Care Setting: Inpatient, Hospital/Acute Care Facility. 
National Quality Forum-endorsed measure. Source
Published By: Elsevier
Elsevier © 2020 6 May 2020
 Document acceptance or rejection of tobacco use discharge treatment  
Guidance
Tobacco Cessation Interventions
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians:
Ask all adults about tobacco use
Advise them to stop using tobacco
Provide behavioral interventions and U.S. Food and Drug Administration (FDA)–approved
pharmacotherapy for cessation to adults who use tobacco
In addition, the USPSTF recommends that clinicians:
Ask all pregnant women about tobacco use
Advise them to stop using tobacco
Provide behavioral interventions for cessation to pregnant women who use tobacco
The USPSTF concludes that the current evidence is insufficient to assess the balance of
benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women.
Also, the USPSTF concludes that the current evidence is insufficient to recommend electronic nicotine
delivery systems (ENDS) for tobacco cessation in adults, including pregnant women. The USPSTF
recommends that clinicians direct patients who smoke tobacco to other cessation interventions with
established effectiveness and safety.
 
Siu AL; U.S. Preventive Services Task Force. . Behavioral and Pharmacotherapy Interventions for Tobacco
Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force
Recommendation Statement. Ann Intern Med. 2015;163(8), 622-634. Source
Published By: Elsevier
Quality Measure
NQF 1651; NQF 1654; NQF 1656. Inpatient tobacco cessation bundle, includes discharge
NQF 1651; NQF 1654; and NQF 1656 are bundled, inpatient quality measures from the Joint Commission
related to tobacco use screening and treatment, and referral to treatment at discharge.
 
1.)  NQF 1651. TOB-1: Tobacco Use Screening. 
Hospitalized patients aged >18 years, who are screened during the hospital stay for tobacco use
(cigarettes, smokeless tobacco, pipe and cigars) within the past 30 days. This measure is intended to
be used as part of a set of linked measures addressing Tobacco Use. Source
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 2.)  NQF 1654. TOB-2: Tobacco Use Treatment Provided or Offered and the subset measure TOB-2a
Tobacco Use Treatment. 
The measure is reported as an overall rate, which includes all hospitalized patients aged >18 years, to
whom tobacco use treatment was provided during the hospital stay, or offered and refused; and a
second rate, a subset of the first, which includes only those patients who received tobacco use
treatment during the hospital stay. These measures are intended to be used as part of a set of
measures addressing Tobacco Use. 
TOB-2: The number of patients who received or refused practical counseling to quit AND received or
refused FDA-approved cessation medications.
TOB-2a: The number of patients who received practical counseling to quit AND received FDA-
approved cessation medications. Source
 
3.)  NQF1656. TOB-3: Tobacco Use Treatment Provided or Offered at Discharge and the subset
measure
TOB-3a: Tobacco Use Treatment at Discharge. The measure is reported as an overall rate which
includes all hospitalized patients aged >18 years, to whom tobacco use treatment was provided, or
offered and refused, at the time of hospital discharge; and a second rate, a subset of the first, which
includes only those patients who received tobacco use treatment at discharge. Treatment at discharge
includes a referral to outpatient counseling and a prescription for one of the FDA-approved tobacco
cessation medications. These measures are intended to be used as part of a set of linked measures
addressing Tobacco Use. 
TOB-3: The number of patients who received or refused evidence-based outpatient counseling AND
received or refused a prescription for FDA-approved cessation medication at discharge.
TOB-3a: The number of patients who were referred to evidence-based outpatient counseling AND
received a prescription for FDA-approved cessation medication at discharge. Source
 
Steward: Joint Commission. National Quality Strategy Priorities: Health and Well-Being.
Care Setting: Hospital/Acute Care Facility.






 Diet: Regular (consistent carbohydrate)
 Diet: Mechanical/dental soft
 Diet: Dysphagia: pureed
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Medications
 Antipyretics
 Acetaminophen Oral Tablet ; 650 mg Every 4 hours for 7 Day(s) (PRN: Temperature greater than 38
degree celsius) (dispense 50 tablet(s); 0 refill(s)) ; Do not exceed 4000 mg acetaminophen in 24
hours from all sources
 Immunizations 
Guidance
Immunization Schedule, Aged 19 Years or Older
Table 1. Recommended Adult Immuniz
ages 19 years or older, United States, 2
Always make recommendations by determining needed vaccines based on
and other indications (Table 2), and reviewing special situations (Notes).
Table 1. By age
Table 2. By indications
Schedule Changes & Guidance
Resources for health care providers
Resources for adults
Download Schedules App
8.5″x11″ print color  [6 pages]
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 Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases
(NCIRD). (2020). Recommended immunization schedule for adults aged 19 years or older, United States. Source
Published By: Elsevier
 Influenza vaccine Injectable Suspension Intramuscular Injectable Suspension; 0.5 mL Once 
Quality Measure
NQF 1659. Influenza Immunization, Inpatient, 6 Months and Older, discharge
Inpatients aged >6 months, discharged during October, November, December, January, February or March,
who are screened for influenza vaccine status and vaccinated prior to discharge, if indicated. 
 
Steward: Centers for Medicare & Medicaid Services.
Use in Federal Program: Hospital Inpatient Quality Reporting. 
Care Setting: Hospital/Acute Care Facility . 
Legend
8.5″x11″ print black and white  [6 pages]
Compliant version of this schedule

Vaccines in the Adult Immunization Schedule
Learn how to display current schedules from your website.
Hard copies of the schedule are available for free using the CDC-info o
Download Schedules App
Recommended vaccination for adults who meet age requirement, lack documentat
Recommended vaccination for adults with an additional risk factor or another indic
Recommended vaccination based on shared clinical decision-making
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National Quality Forum-endorsed measure. Source
Published By: Elsevier
 Pneumococcal polysaccharide vaccine 23 (PPSV23) Injectable Solution Intramuscular Injectable
Solution; 0.5 mL Once
 Pneumococcal conjugate vaccine 13 (PCV13) Prefilled Syringe Intramuscular Prefilled Syringe; 0.5
mL Once
 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid
vaccine, inactivated Intramuscular Injection; 0.5 mL Once
 diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Intramuscular Injection;
0.5 mL Once
 Other
 Provide a referral to outpatient tobacco counseling and a prescription for one of the FDA-approved
tobacco cessation medications, or document refusal  
Guidance
Tobacco Cessation Interventions
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians:
Ask all adults about tobacco use
Advise them to stop using tobacco
Provide behavioral interventions and U.S. Food and Drug Administration (FDA)–approved
pharmacotherapy for cessation to adults who use tobacco
In addition, the USPSTF recommends that clinicians:
Ask all pregnant women about tobacco use
Advise them to stop using tobacco
Provide behavioral interventions for cessation to pregnant women who use tobacco
The USPSTF concludes that the current evidence is insufficient to assess the balance of
benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women.
Also, the USPSTF concludes that the current evidence is insufficient to recommend electronic nicotine
delivery systems (ENDS) for tobacco cessation in adults, including pregnant women. The USPSTF
recommends that clinicians direct patients who smoke tobacco to other cessation interventions with
established effectiveness and safety.
 
Siu AL; U.S. Preventive Services Task Force. . Behavioral and Pharmacotherapy Interventions for Tobacco
Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force
Recommendation Statement. Ann Intern Med. 2015;163(8), 622-634. Source
Published By: Elsevier
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Quality Measure
NQF 1651; NQF 1654; NQF 1656. Inpatient tobacco cessation bundle, includes discharge
NQF 1651; NQF 1654; and NQF 1656 are bundled, inpatient quality measures from the Joint Commission
related to tobacco use screening and treatment, and referral to treatment at discharge.
 
1.)  NQF 1651. TOB-1: Tobacco Use Screening. 
Hospitalized patients aged >18 years, who are screened during the hospital stay for tobacco use
(cigarettes, smokeless tobacco, pipe and cigars) within the past 30 days. This measure is intended to
be used as part of a set of linked measures addressing Tobacco Use. Source
 
2.)  NQF 1654. TOB-2: Tobacco Use Treatment Provided or Offered and the subset measure TOB-2a
Tobacco Use Treatment. 
The measure is reported as an overall rate, which includes all hospitalized patients aged >18 years, to
whom tobacco use treatment was provided during the hospital stay, or offered and refused; and a
second rate, a subset of the first, which includes only those patients who received tobacco use
treatment during the hospital stay. These measures are intended to be used as part of a set of
measures addressing Tobacco Use. 
TOB-2: The number of patients who received or refused practical counseling to quit AND received or
refused FDA-approved cessation medications.
TOB-2a: The number of patients who received practical counseling to quit AND received FDA-
approved cessation medications. Source
 
3.)  NQF1656. TOB-3: Tobacco Use Treatment Provided or Offered at Discharge and the subset
measure
TOB-3a: Tobacco Use Treatment at Discharge. The measure is reported as an overall rate which
includes all hospitalized patients aged >18 years, to whom tobacco use treatment was provided, or
offered and refused, at the time of hospital discharge; and a second rate, a subset of the first, which
includes only those patients who received tobacco use treatment at discharge. Treatment at discharge
includes a referral to outpatient counseling and a prescription for one of the FDA-approved tobacco
cessation medications. These measures are intended to be used as part of a set of linked measures
addressing Tobacco Use. 
TOB-3: The number of patients who received or refused evidence-based outpatient counseling AND
received or refused a prescription for FDA-approved cessation medication at discharge.
TOB-3a: The number of patients who were referred to evidence-based outpatient counseling AND
received a prescription for FDA-approved cessation medication at discharge. Source
 
Steward: Joint Commission. National Quality Strategy Priorities: Health and Well-Being.
Care Setting: Hospital/Acute Care Facility.
National Quality Forum-endorsed measures.
Elsevier © 2020 6 May 2020
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 Smoking Cessation/Tobacco Withdrawal - Ambulatory Module
Referrals
 Referral: Public Health ; History: [add diagnosis, symptom(s)] ; Question: [add reason for
referral/consult]
 Referral: Primary Care; History: [add diagnosis, symptom(s)]; Question: [add reason for referral]
 Referral: Clinical Social Work; History: [add diagnosis, symptom(s)]; Question: [add reason for referral]
 Referral: Alcohol/Substance Abuse Counseling; History: [add diagnosis, symptom(s)]; Question: [add
reason for referral]  
Guidance
Alcohol and Substance Abuse Screening
The U. S. Preventive Services Task Force (USPSTF) recommends that clinicians screen adults aged 18 years or
older for alcohol misuse and provide persons engaged in risky or hazardous drinking with brief behavioral
counseling interventions to reduce alcohol misuse. (Recommendation: Grade B)
 
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of
screening adolescents, adults, and pregnant women for illicit drug use. (Recommendation: Grade I)
 
For alcohol use, briefly screen patients with the four-question CAGE questionnaire, which has been shown to be
effective in identifying problem alcohol use
Two or more affirmative answers to the CAGE questions below (with modifications for drug use) indicate a
high probability of dependence:
1. Have you ever felt that you should Cut down on your drinking (or drug use)?
2. Have people Annoyed you by criticizing your drinking (or drug use)?
3. Have you ever felt bad or Guilty about your drinking (or drug use)?
4. Have you ever had a drink (used drugs) first thing in the morning to steady your nerves or to get
rid of a hangover (Eye-opener)?
Click for CAGE Questions for Alcohol Use
Click for AUDIT-C for Alcohol Use
 
US Preventive Services Task Force. (2013). Published Recommendations for Primary Care Practice. Alcohol
Misuse: Screening and Behavioral Counseling Interventions in Primary Care. Source
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 Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies. Clin
Invest Med. 2007;30(1), 33-41. Source
Published By: Elsevier
Quality Measure
NQF 1664. SUB-3: Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge; SUB-
3a: Alcohol & Other Drug Use Disorder Treatment at Discharge
1. The measure is reported as:
An overall rate, which includes all hospitalized patients aged >18 years, to whom alcohol or drug use
disorder treatment was provided, or offered and refused, at the time of hospital discharge; and
A second rate, a subset of the first, which includes only those patients who received alcohol or drug use
disorder treatment at discharge
2. The Provided or Offered rate (SUB-3) describes patients who:
Are identified with alcohol or drug use disorder
Receive or refuse at discharge a prescription for FDA-approved medications for alcohol or drug use
disorder
Receive or refuse a referral for addictions treatment
3. The Alcohol and Other Drug Disorder Treatment at Discharge (SUB-3a) rate describes only those who receive:
A prescription for FDA-approved medications for alcohol or drug use disorder
Referral for addictions treatment
Those who refused are not included.
4. These measures are intended to be used as part of a set of 4 linked measures addressing Substance Use
(SUB-1 Alcohol Use Screening; SUB-2 Alcohol Use Brief Intervention Provided or Offered; SUB-3 Alcohol and
Other Drug Use Disorder Treatment Provided or Offered at Discharge; SUB-4 Alcohol and Drug Use: Assessing
Status after Discharge)
SUB-3: The number of patients who received or refused at discharge a prescription for medication for treatment
of alcohol or drug use disorder, OR received or refused a referral for addictions treatment.
SUB-3a: The number of patients who received a prescription at discharge for medication for treatment of alcohol
or drug use disorder, OR a referral for addictions treatment.
Steward: The Joint Commission.
Care Setting: Inpatient, Hospital/Acute Care Facility. 
National Quality Forum-endorsed measure. Source
Published By: Elsevier
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 Referral: Smoking Cessation/Tobacco Withdrawal Counseling; History: [add diagnosis, symptom(s)];
Question: [add reason for referral]  
Guidance
Counseling, Smoking Cessation/Tobacco Withdrawal
According to systematic reviews of smoking cessation programs for hospitalized patients:
High-intensity behavioral counseling beginning during hospitalization and continuing for at least 1 month
after discharge was more effective than either usual care or less intensive counseling
The addition of nicotine replacement therapy resulted in further benefit
Preoperative smoking interventions may reduce postoperative morbidity
 
Thomsen T, Villebro N, Møller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst
Rev. 2014;3, CD002294. Source
 
Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane
Database Syst Rev. 2012;5(5), CD001837. Source
Published By: Elsevier
Quality Measure
NQF 1651; NQF 1654; NQF 1656. Inpatient tobacco cessation bundle, includes discharge
NQF 1651; NQF 1654; and NQF 1656 are bundled, inpatient quality measures from the Joint Commission related
to tobacco use screening and treatment, and referral to treatment at discharge.
 
1.)  NQF 1651. TOB-1: Tobacco Use Screening. 
Hospitalized patients aged >18 years, who are screened during the hospital stay for tobacco use
(cigarettes, smokeless tobacco, pipe and cigars) within the past 30 days. This measure is intended to be
used as part of a set of linked measures addressing Tobacco Use. Source
 
2.)  NQF 1654. TOB-2: Tobacco Use Treatment Provided or Offered and the subset measure TOB-2a
Tobacco Use Treatment. 
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The measure is reported as an overall rate, which includes all hospitalized patients aged >18 years, to
whom tobacco use treatment was provided during the hospital stay, or offered and refused; and a second
rate, a subset of the first, which includes only those patients who received tobacco use treatment during
the hospital stay. These measures are intended to be used as part of a set of measures addressing
Tobacco Use. 
TOB-2: The number of patients who received or refused practical counseling to quit AND received or
refused FDA-approved cessation medications.
TOB-2a: The number of patients who received practical counseling to quit AND received FDA-approved
cessation medications. Source
 
3.)  NQF1656. TOB-3: Tobacco Use Treatment Provided or Offered at Discharge and the subset measure
TOB-3a: Tobacco Use Treatment at Discharge. The measure is reported as an overall rate which
includes all hospitalized patients aged >18 years, to whom tobacco use treatment was provided, or offered
and refused, at the time of hospital discharge; and a second rate, a subset of the first, which includes only
those patients who received tobacco use treatment at discharge. Treatment at discharge includes a
referral to outpatient counseling and a prescription for one of the FDA-approved tobacco cessation
medications. These measures are intended to be used as part of a set of linked measures addressing
Tobacco Use. 
TOB-3: The number of patients who received or refused evidence-based outpatient counseling AND
received or refused a prescription for FDA-approved cessation medication at discharge.
TOB-3a: The number of patients who were referred to evidence-based outpatient counseling AND
received a prescription for FDA-approved cessation medication at discharge. Source
 
Steward: Joint Commission. National Quality Strategy Priorities: Health and Well-Being.
Care Setting: Hospital/Acute Care Facility.
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